CIK 0001006281 · Non-accelerated filer<br>Smaller reporting company
Protalix BioTherapeutics, Inc.
Sign in to watch- Ticker
- PLX
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 650643773
- Phone
- 201-696-9345
- Business address
- 2 UNIVERSITY PLAZA, SUITE 100, HACKENSACK, NJ, 07601
- Former names
- ORTHODONTIX INC, EMBASSY ACQUISITION CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2012-05-02 | Maimon Yossi VP, Chief Financial Officer | Option exercise | +50,000 | $2.65 | $133K | 125,964 |
| 2012-05-02 | Maimon Yossi VP, Chief Financial Officer | Sale | −125,964 | $7.13 | $898K | 0 |
| 2012-05-02 | Maimon Yossi VP, Chief Financial Officer | Option exercise · Stock Options (Right to Buy) | −75,964 | 0 | ||
| 2012-05-02 | Maimon Yossi VP, Chief Financial Officer | Option exercise · Stock Options (Right to Buy) | −50,000 | 0 | ||
| 2012-05-02 | Aviezer David President & CEO | Option exercise | +326,267 | $0.12 | $39K | 326,267 |
| 2012-05-02 | Aviezer David President & CEO | Option exercise | +123,733 | $0.97 | $120K | 450,000 |
| 2012-05-02 | Aviezer David President & CEO | Sale | −450,000 | $7.13 | $3.2M | 0 |
| 2012-05-02 | Aviezer David President & CEO | Option exercise · Stock Options (Right to Buy) | −326,267 | 0 | ||
| 2012-05-02 | Aviezer David President & CEO | Option exercise · Stock Options (Right to Buy) | −123,733 | 853,563 | ||
| 2012-05-02 | Almon Einat Brill SVP, Product Development | Option exercise | +116,848 | $0.97 | $114K | 116,848 |
| 2012-05-02 | Almon Einat Brill SVP, Product Development | Option exercise | +50,000 | $2.65 | $133K | 166,848 |
| 2012-05-02 | Almon Einat Brill SVP, Product Development | Sale | −166,848 | $7.13 | $1.2M | 0 |
| 2012-05-02 | Almon Einat Brill SVP, Product Development | Option exercise · Stock Options (Right to Buy) | −116,848 | 0 | ||
| 2012-05-02 | Almon Einat Brill SVP, Product Development | Option exercise · Stock Options (Right to Buy) | −50,000 | 0 | ||
| 2010-10-07 | Maimon Yossi VP, Chief Financial Officer | Sale | −70,000 | $9.67 | $677K | 0 |
| 2010-10-07 | Maimon Yossi VP, Chief Financial Officer | Option exercise | +77,769 | $0.97 | $76K | 0 |
| 2010-10-07 | Maimon Yossi VP, Chief Financial Officer | Shares withheld for taxes | −7,769 | $9.73 | $76K | 0 |
| 2010-10-07 | Maimon Yossi VP, Chief Financial Officer | Option exercise · Stock Options (Right to Buy) | −77,769 | 75,964 | ||
| 2010-10-06 | Almon Einat Brill VP, Product Development | Sale | −15,000 | $9.29 | $139K | 0 |
| 2010-10-06 | Almon Einat Brill VP, Product Development | Option exercise | +70,000 | $0.97 | $68K | 0 |
Page 8 of 33 · 654 trades